High expression of CXCR4, CXCR7 and SDF-1 predicts poor survival in renal cell carcinoma

World Journal of Surgical Oncology

Research

Yang Wang¹  Li Gao¹  Bing Liu²  Zhenjie Wu²  Qing Yang²  Yinghao Sun²  Wei Chen²  Linhui Wang² 

[1] The Department of Pathology, Changhai Hospital, Second Military Medical University, Shanghai, China;The Department of Urology, Changhai Hospital, Second Military Medical University, Shanghai, China;

关键词: CXCR4;    CXCR7;    SDF-1;    Renal cell carcinoma;    Prognosis;   

DOI  :  10.1186/1477-7819-10-212

 received in 2012-08-17, accepted in 2012-09-26,  发布年份 2012

来源: Springer

【 摘 要 】

BackgroundChemokines and their receptors are known to play important roles in the tumorigenesis of many malignancies. The aim of this study was to evaluate the prognostic impact of the expression of the chemokine SDF-1 and its receptors CXCR4 and CXCR7 in patients with renal cell carcinoma.MethodsThe expression of CXCR4, CXCR7 and SDF-1 in specimens from 97 renal cell carcinoma patients was evaluated by immunohistochemistry on a tissue microarray. These results were correlated with the clinicopathological parameters and survival of the patients.ResultsCXCR4 and CXCR7 were expressed in all patients, whereas SDF-1 was expressed in 61 patients (62.9%). No association was observed between the expression of CXCR4, CXCR7 or SDF-1 and the clinical or pathological data except between SDF-1 expression and Fuhrman’s grade (P = 0.015). Patients with high expression of CXCR4, CXCR7 and SDF-1 had shorter overall survival and recurrence-free survival than those with low expression. In a multivariate analysis, the high expression of CXCR4, CXCR7 and SDF-1 correlated with poor overall survival and recurrence-free survival independent of gender, age, AJCC stage, lymph node status, metastasis, histologic variant and Fuhrman’s grade.ConclusionsHigh levels of CXCR4, CXCR7 and SDF-1 were associated with poor overall survival and recurrence-free survival in renal cell carcinoma patients. CXCR4, CXCR7 and SDF-1 may serve as useful prognostic markers and therapeutic targets for renal cell carcinoma.

【 授权许可】

Unknown   
© Wang et al.; licensee BioMed Central Ltd. 2012. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.